Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.17−0.71 (-2.64%)
Close on Nov 18, 2026Market cap $3.34BP/E –Yield –
Viking Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Viking Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$462.63M. For fiscal 2025 it was -$278.69M. The highest annual figure on record is -$1.59M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$278.69M | – |
| FY2024 | Dec 31, 2024 | -$87.79M | – |
| FY2023 | Dec 31, 2023 | -$73.38M | – |
| FY2022 | Dec 31, 2022 | -$48.40M | – |
| FY2021 | Dec 31, 2021 | -$47.59M | – |
| FY2020 | Dec 31, 2020 | -$21.78M | – |
| FY2019 | Dec 31, 2019 | -$24.75M | – |
| FY2018 | Dec 31, 2018 | -$18.76M | – |
| FY2017 | Dec 31, 2017 | -$14.76M | – |
| FY2016 | Dec 31, 2016 | -$11.07M | – |
| FY2015 | Dec 31, 2015 | -$8.73M | – |
| FY2014 | Dec 31, 2014 | -$1.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$138.19M | – |
| Q2 FY2026 | Jun 30, 2026 | -$125.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$113.98M | – |
| Q4 FY2025 | Dec 31, 2025 | -$85.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$94.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.96M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.44M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.40M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.68M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.30M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.33M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.20M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.46M | – |
See a number that looks wrong?